- Home
- CATX
as 11-21-2025 3:41pm EST
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
| Founded: | 1983 | Country: | United States |
| Employees: | N/A | City: | SEATTLE |
| Market Cap: | 239.0M | IPO Year: | N/A |
| Target Price: | $11.73 | AVG Volume (30 days): | 2.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.45 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.60 - $5.39 | Next Earning Date: | 11-10-2025 |
| Revenue: | $1,075,000 | Revenue Growth: | -30.96% |
| Revenue Growth (this year): | -20.29% | Revenue Growth (next year): | -22.87% |
Stock Insider Trading Activity of Perspective Therapeutics Inc. (CATX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hunt Jonathan Robert | CATX | Chief Accounting Officer | Nov 13 '25 | Buy | $2.03 | 11,000 | $22,294.80 | 59,800 | |
| Williamson Robert F III | CATX | Director | Nov 12 '25 | Buy | $2.10 | 9,498 | $19,945.80 | 9,864 |
Latest Perspective Therapeutics Inc. News
CATX Breaking Stock News: Dive into CATX Ticker-Specific Updates for Smart Investing
Associated Press Finance
13 days ago
Perspective Therapeutics: Q3 Earnings Snapshot
GlobeNewswire
13 days ago
Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results
Zacks
18 days ago
Stevanato Group (STVN) Q3 Earnings and Revenues Surpass Estimates
Zacks
19 days ago
Rigel Pharmaceuticals (RIGL) Tops Q3 Earnings and Revenue Estimates
GlobeNewswire
a month ago
Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results
Simply Wall St.
a month ago
Could CATX’s New ESMO Data Reveal a Shift in Its Long-Term Oncology Innovation Strategy?
GlobeNewswire
4 months ago
Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results
MT Newswires
5 months ago
B. Riley Raises Price Target on Perspective Therapeutics to $12 From $9, Keeps Buy Rating
Compare CATX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CATX Perspective Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.